We have demonstrated that a single injection of interleukin ( 
Introduction
IL-12 induces T helper (Th1) 1 -associated responses by stimulating T cells and natural killer (NK) cells to produce IFN-␥ (1-4). Recent studies in a parent → nonirradiated F1 bone marrow transplantation (BMT) model have shown that IL-12 plays a critical role in the development of acute graft-versushost disease (GVHD; references 5-7). In contrast, we have recently demonstrated that a single injection of IL-12 on the day of BMT paradoxically inhibits acute GVHD in lethally irradiated mice receiving fully allogeneic or haploidentical BMT (8) (9) (10) . This GVHD protection is associated with a reduction in the GVHD-associated expansion and activation of donor Th cells reacting to host antigens (11) .
IFN-␥ , the production of which is regulated by IL-12 (1, 2, 4), plays an important role in mediating the biological effects of . Previous reports on the role of IFN-␥ in acute GVHD have been conflicting. In contrast to studies showing an important role for IFN-␥ in the induction of GVHD (16) (17) (18) (19) (20) , exogenous IFN-␥ has been previously shown to inhibit GVHD (21) . Also, despite studies suggesting an important role for IFN-␥ in the pathogenesis of GVHD-associated immunodeficiency (22) (23) (24) (25) , IFN-␥ has been shown to improve immunocompetence (26) and protect from infections (27) in allogeneic BMT recipients. We have recently reported that IL-12 treatment has a biphasic effect on serum IFN-␥ levels in murine GVHD models, leading to an early increase on days 2 and 3, followed by an almost complete inhibition on day 4, when serum IFN-␥ levels peak in untreated GVHD controls (8) . IL-12-mediated GVHD protection can be completely abolished by administration of neutralizing anti-IFN-␥ mAb (9) , indicating that IFN-␥ plays an essential role in the inhibitory effect of IL-12 on GVHD.
We have now made use of IFN-␥ -deficient mice to determine the mechanism by which IFN-␥ mediates the protective effect of IL-12 against GVHD and to determine whether donor-or host-derived IFN-␥ is responsible for this effect of IL-12. The results show that IL-12-mediated GVHD protection is dependent on donor-derived IFN-␥ production. Inhibition of GVHD-associated activation of antihost Th responses related to IL-12 treatment in recipients of wild-type (WT) BALB/c BMT was significantly reduced in recipients of IFN-␥ gene knockout (GKO) BALB/c BMT. Thus, donor-derived IFN-␥ plays a critical role in the inhibition of donor Th responses associated with IL-12-induced GVHD protection. Furthermore, our studies show definitively that lethal acute GVHD can develop in lethally irradiated mice in the complete absence of IFN-␥ .
Methods
Mice. Specific pathogen-free WT and GKO female C57BL/6 (B6, BMT. Recipient mice were lethally irradiated (9.75 Gy, 137 Cs source, 0.89 Gy/min) and reconstituted within 4 to 8 h with a single 1-ml intravenous inoculum containing 5 ϫ 10 6 T cell-depleted (TCD) B6 bone marrow cells (BMC), 7.5 ϫ 10 6 BALB/c BMC, and 20 ϫ 10 6 BALB/c spleen cells, or with 5 ϫ 10 6 TCD B6 BMC alone (syngeneic control group). T cell depletion was performed by incubating cells with anti-CD4 mAb (GK1.5 ascites) and anti-CD8 mAb (2.43 ascites) followed by rabbit complement (28) . The completeness of depletion was verified by flow cytometry (FCM) as previously described (10) . In one experiment (see Fig. 3 ), B6 mice received 5 ϫ 10 6 B6 TCD BMC plus CD4 cell-depleted (with GK1.5 plus complement) or rabbit complement-treated BALB/c BMC (5 ϫ 10
6
) and spleen cells (10 ϫ 10 6 ). To avoid bias from cage-related effects, animals were randomized before and after BMT as described (29) .
IL-12 administration. Murine recombinant IL-12 (provided by Genetics Institute, Cambridge, MA), with a specific activity of 4.9-5.5 ϫ 10 6 U/mg, was injected intraperitoneally into recipient mice (2,500 IU/mouse) in a single injection ‫ف‬ 1 h before BMT.
FCM analysis of donor T cell expansion and activation. Recipient mice were killed at varying times after BMT, and single-cell suspensions of spleen cells were prepared. Cells were stained for 30 min at 4 Њ C with FITC-conjugated mAb specific for activation markers (anti-CD69 mAb H1. antigen-responsive Th, and statistical analysis was performed by chi square minimization analysis as described by Taswell (31) .
Statistical analysis. Statistical analysis of survival data was performed with the log rank test. Student's t test was used to determine the level of significance of differences in group means. A P value of Ͻ 0.05 was considered to be significant in both types of analyses.
Results

Lethal acute GVHD can be induced in the absence of IFN-␥ .
To compare the development of acute lethal GVHD in the presence and absence of IFN-␥ , WT or GKO B6 mice were lethally irradiated (9.75 Gy) and reconstituted with 5 ϫ 10 6 TCD syngeneic BMC plus allogeneic BMC (7.5 ϫ 10
6
) and spleen cells (20 ϫ 10 6 ) from WT or GKO BALB/c mice. Lethally irradiated WT or GKO B6 mice injected with 5 ϫ 10 6 TCD syngeneic BMC alone served as controls. Survival is shown in Fig. 1 . The GKO B6 recipients of WT BMT (WT → GKO) showed survival curves similar to those of WT B6 recipients injected with WT inocula (WT → WT), demonstrating that host-derived IFN-␥ has no significant effect on the onset of acute GVHD (Fig. 1) . Fig. 1 also shows that GKO BALB/c T cells were capable of inducing lethal acute GVHD after injection into lethally irradiated B6 mice. In WT → WT BMT recipients, the majority of GVHD-related deaths occurred before day 10 after BMT (median survival time [MST] ϭ 8 d). Mortality was slightly delayed ( P Ͻ 0.05) in WT recipients of GKO BALB/c inocula (GKO → WT), with Ͼ 80% of animals succumbing between 10 and 14 d after BMT (MST ϭ 12 d; Fig. 1 A ) . A similar trend was observed in GKO B6 recipients of GKO BMT (GKO → GKO; MST ϭ 12 d) compared to GKO B6 mice receiving WT BMT (MST ϭ 8 d), but this difference was not statistically significant ( P ϭ 0.7; Fig. 1 B ) . No difference in survival rates was observed between WT and GKO B6 recipients of GKO BMT, and all animals succumbed by 14 d after BMT (Fig. 1 ). These results demonstrate that, while IFN-␥ may increase the rate of early GVHD mortality, rapidly lethal acute GVHD can occur in the complete absence of IFN-␥ .
IL-12-mediated protective effect against GVHD is dependent on donor-derived IFN-␥ . Previous studies have shown that a single injection of IL-12 on the day of BMT prevents acute GVHD mortality in the A/J → B10 (or B6) fully MHC plus multiple minor antigen-mismatched strain combination, and in the CBD2F1 → B6D2F1 full haplotype-mismatched strain combination (8) (9) (10) . To evaluate the role of donor-and hostderived IFN-␥ in IL-12-induced GVHD protection, we made use of BALB/c and B6 WT and GKO mice. As we have ob- served in other strain combinations, a single injection of IL-12, administered on the day of BMT, induced marked protection against GVHD in the WT BALB/c→B6 strain combination (Fig. 2 A) . Survival in both WT and GKO B6 recipients of WT BALB/c cells (WT→WT and WT→GKO) was significantly prolonged, and to a similar extent, by treatment with IL-12 (P Ͻ 0.001 compared to the control group without IL-12; Fig. 2, A  and B) . However, IL-12 had no effect on GVHD induced by GKO BALB/c cells in WT B6 recipients (Fig. 2 C ; P ϭ 0.3). Furthermore, IL-12 significantly accelerated GVHD mortality in GKO B6 recipients of GKO BALB/c BMT (MST ϭ 7; P Ͻ 0.005) as compared to untreated controls (MST ϭ 12 d; Fig. 2  D) . Therefore, the inhibitory effect of IL-12 on the development of lethal acute GVHD was dependent on donor-derived IFN-␥, and in the complete absence of IFN-␥ (GKO→GKO), IL-12 significantly accelerated GVHD mortality. Apparently, host-derived IFN-␥ overcame the ability of IL-12 to accelerate GVHD mortality in WT recipients of GKO BMT. However, the comparable level of protection induced by IL-12 in WT and GKO B6 recipients of WT BMT indicates that hostderived IFN-␥ was not required for IL-12 to mediate a protective effect against GVHD (Fig. 2) .
Differential effect of IL-12 on the expansion and activation of allogeneic donor T cells from WT and GKO mice.
Previous studies in the A/J→B6 BMT model, in which the early development of acute GVHD is dependent on donor CD4 ϩ cells (28) , have shown that IL-12-mediated GVHD protection is associated with inhibition of the expansion and activation of donor Th cells that is evident in GVHD controls on days 4 and/or 5 after BMT (11) . As shown in Fig. 3 , the induction of acute GVHD in the BALB/c→B6 strain combination is also largely dependent on donor CD4 ϩ cells. Lethally irradiated B6 mice receiving BALB/c BMC (5 ϫ 10 6 ) and spleen cells (10 ϫ 10 6 ), from which CD4 ϩ cells were depleted before BMT by anti- CD4 mAb plus complement, showed no GVHD mortality by 100 d after BMT. In contrast, Ͼ 60% of control B6 recipients of complement-treated BALB/c BMC (5 ϫ 10 6 ) and spleen cells (10 ϫ 10 6 ) died of GVHD by 14 d after BMT (Fig. 3 A) . However, marked weight loss was observed in B6 recipients of CD4-depleted inocula as early as day 8 after BMT, indicating that CD8 ϩ cells induced a milder form of acute GVHD (Fig. 3  B) . These results demonstrate that both CD4 ϩ and CD8 ϩ cells are involved in GVHD induction, but that donor CD4 ϩ cells are critical in causing acute GVHD mortality in this strain combination.
Based on these observations and on our previous studies in the A/J→B6 model, we hypothesized that the differential effect of IL-12 on the development of lethal acute GVHD induced by WT and GKO donor cells might reflect differences in the effect of IL-12 on the expansion and activation of donor CD4 ϩ cells from WT and GKO mice. To determine whether or not donor-derived IFN-␥ was required for this effect of IL-12, WT B6 recipient mice were killed on days 4, 5, 7, and 10 after BMT, and the expansion and activation of donor T cells was compared in IL-12-treated and untreated control recipients of WT or GKO BALB/c cells. Expression of CD69 and CD25, which is expressed early and transiently by activated T cells, and VLA4, a late activation marker, were studied in threecolor flow cytometric analyses. IL-12 treatment led to marked reductions in the number of total donor CD4 ϩ cells and in the number of activated donor CD4 ϩ cells (CD69
) in spleens of WT BALB/c→WT B6 recipients on days 4 and 5 after BMT compared to untreated GVHD controls (Fig. 4, top) . By day 7, the numbers of donor CD4
ϩ cells had declined in spleens of GVHD controls, and no difference was observed between IL-12-treated mice and GVHD controls in the total numbers or in numbers of activated donor CD4 ϩ cells. Different kinetics of donor CD4
ϩ cell expansion and activation were observed in untreated recipients of GKO BMT compared to untreated recipients of WT BMT. The numbers of total and activated donor CD4 ϩ cells in spleens of GKO→WT BMT recipients were highest on day 4 and declined thereafter, whereas in WT→WT BMT recipients, these numbers were stable or increased between days 4 and 5. With the exception of CD69 ϩ
CD4
ϩ cells, which were significantly higher in spleens of WT→WT BMT than GKO→WT BMT recipients at all time points studied, no significant difference was observed between the two groups in the numbers of total and activated donor CD4 ϩ cells on day 4 after BMT. However, the numbers of these cells became significantly higher in spleens of WT→WT BMT than GKO→WT BMT recipients on day 5 after BMT (Fig. 4) .
The effects of IL-12 on donor CD4 ϩ cell numbers were quite different in GKO→WT BMT recipients than in WT→ WT BMT recipients. In the GKO→WT BMT group, IL-12 treatment also led to significant reductions in the total numbers of donor CD4 ϩ cells in the spleen compared to controls ϩ cells that expressed these activation makers as measured by FCM analysis (5F1
. Each group includes three to seven animals at each time point, and data are presented as group means (ϮSD). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.005 for the indicated control group compared to the IL-12-treated group receiving the same BMT inoculum. on day 4 after BMT (P Ͻ 0.005; Fig. 4, bottom left) . However, the numbers of donor CD4 ϩ cells in the spleens of the IL-12-treated GKO→WT BMT recipients were significantly greater than those in IL-12-treated WT B6 recipients of WT BALB/c BMC and spleen cells (P Ͻ 0.01). Furthermore, by day 5, the total numbers of donor CD4 ϩ cells were significantly higher in spleens of IL-12-treated mice than in those of control recipients of GKO inocula (P Ͻ 0.05; Fig. 4, bottom) . This increase was still apparent on day 7 after BMT (P Ͻ 0.05).
Although a slight reduction in the number of CD25 ϩ CD4 ϩ donor T cells was seen in spleens of IL-12-treated GKO→WT B6 recipients as compared to untreated controls on day 4 after BMT, this difference did not reach statistical significance.
In
ϩ cells were also observed in IL-12-treated recipients of GKO BMT as compared to untreated controls by day 5 (Fig. 4, bottom) . In addition, the numbers of activated donor CD4 ϩ cells were markedly higher in IL-12-treated GKO→WT recipients than in IL-12-treated WT→WT recipients on day 4 or days 4 and 5 after BMT (Fig. 4) . Together, these results suggest that donor-derived IFN-␥ plays an important role in the inhibitory effects of IL-12 on the expansion and activation of donor CD4
ϩ cells. At a later time point (day 10), after non-IL-12-treated control recipients of WT inocula had succumbed to GVHD, greater numbers of total and activated donor CD4 ϩ cells were detected in spleens of IL-12-treated WT→WT recipients than were detected on day 7 (Fig. 4, top) . These numbers were markedly reduced in IL-12-treated recipients of GKO BMC and spleen cells (Fig. 4, bottom) .
The
ϩ cells in spleens of untreated GKO→WT BMT recipients were higher than those in untreated WT→WT BMT recipients on days 4 and/or 5 after BMT, but these differences were not statistically significant. In recipients of WT BMT, IL-12 induced a similar delay in the expansion and activation of donor CD8 ϩ cells to that observed for donor CD4 ϩ cells in comparison to GVHD controls (Fig. 5, top) . However, IL-12 more efficiently delayed the proliferation and activation of GKO donor CD8 ϩ cells (Fig. 5, bottom) than of CD4 ϩ cells from the same donors (Fig. 4, bottom) . A significant reduction in numbers of CD8 
CD8
ϩ cells became higher in spleens of IL-12-treated than control recipients of GKO BMT (P Ͻ 0.05). In addition, the numbers of total and activated donor CD8 ϩ cells were greater on days 4 and 5 in IL-12-treated recipients of GKO BMT than in similarly-treated recipients of WT BMT (Fig. 5) . Thus, the magnitude of IL-12-mediated inhibition of the expansion and activation of GKO donor CD8 ϩ cells was less marked than its effect on WT donor CD8 ϩ cells. Since donor CD4 ϩ cells are critical for the induction of acute GVHD in this strain combination (Fig. 3) , reduced expansion and activation of donor CD8 ϩ cells alone by IL-12 in recipients of GKO BMT failed to mediate a protective effect against GVHD (Fig. 2) . Similar to CD4 ϩ cells, a later expansion (day 10 after BMT) of donor CD8 ϩ T cells was observed in spleens of IL-12-treated recipients of WT BALB/c BMC and spleen ϩ cells in recipient spleen were calculated in a similar manner as that for donor CD4 ϩ cells, as described in the legend of Fig. 4 . Each group includes three to seven animals at each time point, and data are presented as group means (ϮSD). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.005 for the indicated control group compared to the IL-12-treated group receiving same BMT inoculum. cells. Previous studies in another strain combination, in which the development of acute GVHD is also dependent on donor CD4 ϩ T cells, have shown that CD8 ϩ T cell-mediated antihost CTL activity is extremely low in GVHD controls, and is unaffected by IL-12 treatment (11) . Consistently, the expanded donor CD8 ϩ T cells detected in spleens of IL-12-treated recipients of WT BALB/c BMT on day 10 showed no antihost CTL activity, as measured by LDA (data not shown).
IL-12 inhibits antihost Th responses of allogeneic WT Th cells, but not of GKO Th cells.
LDA was used to compare the frequencies of activated host-reactive Th cells in control and IL-12-treated recipients of WT and GKO BMT. Similar to results we have obtained in another strain combination (11), a very high frequency of host-reactive activated Th cells was detected in spleens of GVHD controls. The total numbers of host-reactive Th cells per recipient spleen were markedly reduced in IL-12-treated recipients of WT BMT compared to controls on days 4 and 5 (Table I) , similar to our previous results in a different strain combination (11) . Despite a subsequent increase in the number of donor CD4 ϩ cells observed in spleens of IL-12-protected mice on day 10 after BMT (Fig. 4,  top) , these cells showed weaker antihost responses than those of non-IL-12-treated controls on days 4 and 5 (Table I) . Since most untreated WT BALB/c→WT B6 recipients succumbed to GVHD by day 10 after BMT, no data were obtained at day 10 from these mice.
The kinetics of the antihost Th response were quite different in recipients of GKO BMT compared to recipients of WT BMT. Although these responses increased between days 4 and 5 in the latter group, antihost Th responses were highest at day 4 in recipients of GKO BMT, at which time they were greater than the responses in recipients of WT BMT. The antihost Th response declined thereafter in recipients of GKO BMT. These differing kinetics of antihost Th expansion and/or activation were reflected in the kinetics of CD4 ϩ cell numbers, as well as numbers of CD4 ϩ
CD25
ϩ and CD4 ϩ VLA4 ϩ cells in the spleens of the two groups (Fig. 4) .
Consistent with the results in Fig. 4 (bottom) showing that IL-12 treatment led to a reduction in the total number and the number of activated donor CD4 ϩ cells on day 4 in recipients of GKO BMT, a reduction in antihost-activated Th was observed in IL-12-treated compared to control recipients of GKO BMT at this time (Table I) . However, the levels of host-reactive Th cells in the spleens of these mice increased significantly by day 5, becoming higher than those in untreated control recipients, and markedly greater than those in IL-12-protected recipients of WT BMT (P Ͻ 0.05, Table I ). By day 10 after BMT, perhaps due to activation-induced cell death or to the trafficking of donor T cells into GVHD target tissues, the number of hostreactive Th cells had declined significantly in both untreated and IL-12-treated recipients of GKO BMT, and was not different between the two groups ( Table I ). The kinetics of hostreactive Th responses in both control and IL-12-treated recipients of GKO BMT showed a correlation with the numbers of total and activated donor CD4 ϩ cells (Fig. 4) . Overall, our results demonstrate that IL-12 has a lesser inhibitory effect on GVHD-associated host-reactive Th activation and expansion in recipients of GKO BMT compared to recipients of WT BMT. Thus, donor-derived IFN-␥ is required for maximal inhibition of antihost Th responses in IL-12-treated allogeneic BMT recipients.
IFN-␥-independent inhibitory effect of IL-12 on antihost responses of donor T cells.
Despite the lesser extent to which IL-12 altered donor T cell expansion and activation in recipients of GKO compared to WT BMT, the recipients of GKO BMT nevertheless showed some degree of inhibition with IL-12 treatment (Figs. 4 and 5, and Table I ). This inhibition was most apparent at day 4 after BMT. To determine whether IL-12-induced inhibition of donor T cells in WT B6 recipients of GKO BMT might be mediated by host-derived IFN-␥, we repeated this study in the GKO BALB/c→GKO B6 combination. Again, a significant reduction in the total numbers of T cells, in the numbers of activated donor CD4 ϩ and CD8 ϩ cells (Fig. 6) , and in the levels of activated host-reactive Th cells (Table II) was observed in IL-12-treated compared to control mice on day 4 after BMT. Because both recipients and donors in this study were deficient in IFN-␥ production, these results demonstrate that IL-12 can inhibit the early expansion and activation of donor T cells and host-reactive Th activities in the complete absence of IFN-␥. However, this early inhibitory effect of IL-12 on donor T cells by day 4 after BMT was not associated with a reduction in GVHD-induced mortality, as GVHD mortality was similar in IL-12-treated and control WT recipients of GKO BMT (Fig. 2 C) , and was even accelerated in IL-12-treated compared to untreated GKO recipients of GKO BMT (Fig. 2 D) .
Discussion
The data presented here demonstrate that IL-12-induced protection against GVHD-associated mortality is dependent on IFN-␥ produced by allogeneic donor cells. IL-12 mediated significant protection from GVHD only when WT mice were used as allogeneic donors and not when GKO mice were used. Our previous studies in the A/J to B6 strain combination have The host-reactive Th frequencies of some or all samples in the indicated groups were higher than the countable range of the assay (i.e., Ͼ 1/123 cells, the lowest cell concentration in this LDA assay), and the frequencies of these samples were calculated as Ͼ 1/123.
shown that the expansion and activation of donor T cells, especially of CD4 ϩ cells on days 4 and/or 5, is correlated with the rate of acute GVHD mortality, and that inhibition of this donor T cell expansion and activation is associated with the IL-12-mediated protective effect against GVHD (11) . Consistent with these results, this study demonstrated that donor-derived IFN-␥ is required for maximal inhibition of the expansion and activation of donor CD4 ϩ cells (Fig. 4) and of antihost Th responses (Table I) in IL-12-treated BMT recipients. Although IL-12 treatment also reduced the expansion and activation of host-reactive donor T cells that occurred by day 4 after BMT via an IFN-␥-independent mechanism (Figs. 4-6 , and Tables I  and II) , no clinically apparent inhibitory effect against GVHD was associated with IL-12 treatment in recipients of GKO BMT (Fig. 2) . Importantly, by day 5, the total number, the number of activated donor CD4 ϩ T cells, and the level of hostreactive Th cells in IL-12-treated recipients of GKO BMT increased to similar or higher levels than those in untreated controls (Fig. 4 and Table I ). Thus, the failure of IL-12 to protect recipients of GKO BMT against GVHD is associated with early (by day 5) rebound of antihost CD4 responses in the absence of donor-derived IFN-␥. Consistent results were observed in the A/J→B6 combination, in which administration of neutralizing anti-IFN-␥ mAb (5 g) into BMT recipients on day 1 after BMT markedly attenuated the inhibitory effect of IL-12 on donor T cell activation and expansion, and diminished the IL-12-mediated protective effect against GVHD (data not shown). These results demonstrate that IL-12, an immunostimulatory cytokine, can paradoxically inhibit the activation and expansion of alloreactive T cells, and that the maximal inhibitory effect is dependent on IFN-␥.
As is shown in Fig. 4 (top) , the numbers of activated donor CD4 ϩ T cells increased markedly in spleens of IL-12-treated WT→WT BMT recipients between days 7 and 10 after BMT.
This later increase may reflect antigen-driven donor T cell expansion that is delayed by IL-12, or may result from the retention of donor T cells in the spleen, perhaps due to a defect in trafficking to GVHD target tissues. In contrast to IL-12-treated WT→WT BMT recipients, the numbers of activated donor CD4
ϩ T cells were very low in spleens of IL-12-treated and control GKO→WT recipients on day 10 (Fig. 4, bottom) . Thus, it is likely that donor-derived IFN-␥ is required for the later increase in donor T cells in spleens of IL-12-treated WT→WT BMT recipients, raising the possibility that donorderived IFN-␥ might protect from GVHD by delaying donor T cell activation and/or by preventing the trafficking of donor T cells from spleen to GVHD target tissues. In addition, we do not know the basis for the discrepancy between the later (day 10) increase in donor CD4
ϩ T cells observed in conjunction with the lower antihost responses of these cells in spleens of IL-12-treated WT→WT BMT recipients compared to those observed in controls on day 5, when T cell numbers in the spleen were similar to those of IL-12-treated mice on day 10 ( Fig. 4 and Table I ). Because the proliferation of CTLL indicator cells used in our LDA assay is dependent on IL-2 or IL-4, the relatively low frequency of host-reactive Th cells in IL-12-treated mice on day 10 could reflect a failure of activated T cells to produce these cytokines so that their antihost responses were not measurable. Perhaps these cells mature later to cause delayed GVHD mortality. However, a similar discrepancy has been observed in IL-12-treated BMT recipients in the CBD2F1→B6D2F1 strain combination, in which IL-12 permanently prevents both acute and chronic GVHD (Yang, Y.-G., B. Dey, and M. Sykes, unpublished data; and reference 10). Thus, the activated CD4 ϩ T cells detected later in spleens of IL-12-treated mice may be relatively deficient in antihost effector function. Further studies will be needed to determine the reactivity and GVHD potential of these cells. Figure 6 . IL-12 induces early (day 4) inhibition of donor T cell expansion and activation via an IFN-␥-independent mechanism. Spleen cells were prepared from GKO BALB/c→GKO B6 recipients with no further treatment or with IL-12 treatment on day 4 after BMT. The numbers of total and activated donor CD4 ϩ (A) and CD8 ϩ (B) cells in recipient spleen were calculated as described in the legends of Figs. 4 and 5, and data are presented as group means (n ϭ 3 for each group). *P Ͻ 0.05 compared to nontreated controls.
Table II. IL-12 Reduces Host-reactive Th Frequencies on Day 4 via an IFN-␥-independent Mechanism
No. Th per spleen (ϫ1,000)* 63.3Ϯ37. The host-reactive Th frequencies in the recipient spleens of indicated groups were higher than the countable range of the assay (i.e., Ͼ 1/123 cells, the lowest cell concentration in this LDA assay), and the frequencies of these samples were calculated as Ͼ 1/123.
Although this study cannot rule out the possibility that host-derived IFN-␥ contributes to IL-12-mediated GVHD protection in other strain combinations, the data presented here indicate that host-derived IFN-␥ is not required for the protective effect of IL-12 against GVHD, and that hostderived IFN-␥ alone is unable to mediate the GVHD protective effect of IL-12 (Fig. 2) . The lack of an inhibitory effect of IL-12 on GVHD in WT recipients of GKO BMT might be due to a failure of host-derived IFN-␥ to be produced in sufficient amounts. Although previous studies in the A/J→B10 strain combination have shown that although in vivo depletion of host NK cells with anti-NK1.1 mAb PK136 reduced the early (day 2) rise in serum IFN-␥ levels usually observed in IL-12-treated mice (8) , this inhibition was incomplete and failed to abrogate IL-12 protection (our unpublished data). However, in the B10.A→B10 combination in which NK cells from both donor and host express NK1.1 and can be depleted by NK1.1-specific mAb PK136, we observed that depletion of both donor and host NK cells markedly suppressed the IL-12-induced early increase in IFN-␥ production and abrogated IL-12-mediated GVHD protection (Dey, B., Y.-G. Yang, M. Sykes, manuscript in preparation). These results indicate that donor NK cells may play an important role in the IL-12-induced protective effect against GVHD. Consistent with a protective role for donor NK cells in the BALB/c→B6 model used here, we have observed that the addition of WT BALB/c spleen cells to GKO BALB/c BMC/splenocyte inocula allows IL-12 to induce GVHD protection in WT B6 recipients. This protective effect is preserved when CD4, CD8, or both CD4 and CD8 T cells are depleted from WT spleen cell populations (data not shown).
IFN-␥ has been shown to play a critical role in the development of acute GVHD by activating macrophages to produce proinflammatory cytokines such as TNF-␣ and IL-1 (16) (17) (18) (19) (20) 32) . Consequently, acute GVHD has been linked to the activation of alloreactive Th1 cells that produce IFN-␥ (33, 34). However, not all studies support this simple Th1-Th2 paradigm in the pathogenesis of GVHD. For example, treatment with IL-10 led to inhibition of Th1 responses and IFN-␥ production in allogeneic BMT recipients, but had no protective effect against GVHD-associated weight loss and mortality (35) . In addition, administration of exogenous IFN-␥ has been shown to markedly inhibit GVHD (21) , and results from our own and others studies have shown that neutralizing IFN-␥ with mAb has no significant inhibitory effect on the development of acute GVHD (9, 36) . A recent study in a parent→non-irradiated F1 BMT model, in which GKO mice were used as BMT donors and WT mice were used as recipients, has shown that lethal GVHD can be induced in the absence of donorderived IFN-␥ (37). However, the results from that study suggested that donor-derived IFN-␥ played a critical role in the induction of lethal acute GVHD, as most mice receiving GKO BMT died chronically between days 50 and 90 after BMT, whereas the recipients of WT BMT died 15 to 20 d after BMT (37) . In this study, we show clearly that IFN-␥ is not critical for the induction of acute GVHD. The studies in GKO→GKO BMT demonstrate that lethal acute GVHD can be induced in the complete absence of IFN-␥ (Fig. 2 D) .
Although IFN-␥ plays an important role in the induction of Th1 development by IL-12 (15), IL-12 has been shown to be capable of inducing the development of Th1 cells and suppressing Th2 development independently of IFN-␥ (15, 38-40). Therefore, GKO T cells could develop toward either Th1 (at least with respect to IL-2 production) or Th2 cells after alloantigen stimulation. Although previous studies have suggested that Th1 cells play a critical role in the development of acute GVHD (33, 34) , we have obtained results in signal transducer and activator of transcription factor (STAT)4-and STAT6-deficient mice suggesting that both Th1 and Th2 contribute to acute GVHD (our unpublished data). This study has not identified whether or not GKO and WT T cells induce GVHD via distinct mechanisms, or whether or not cytokine production patterns differ. Spleen cells from GKO mice have been shown to exhibit enhanced alloreactivity compared to WT cells in both mixed lymphocyte reaction (MLR) and CTL assays (41) . Consistent with these observations, antihost Th responses were higher on day 4 in recipients of GKO BMT than in mice receiving WT BMT (Table I) , and it is possible that peak responses may have occurred earlier than day 4. The kinetics of GVHD mortality (Fig. 1) and antihost responses of donor CD4 ϩ cells (Fig. 4 and Table I ) differed in recipients of WT and GKO BMT, suggesting that the pathogenesis of GVHD induced by WT and GKO donor T cells might be not identical. The differential effect of IL-12 on GVHD in the two groups might reflect the presence of distinct effector mechanisms in the presence and absence of IFN-␥.
Fas expression on donor T cells in allogeneic BMT recipients is increased by treatment with IL-12, and IL-12-induced GVHD protection is partly dependent on the expression of functional Fas molecules by the donor (11) . Thus, donor T cell apoptosis is one of the likely mechanisms for IL-12-induced GVHD protection. IFN-␥ plays an important role in regulating the death of activated T lymphocytes (42) (43) (44) . A recent study using a Th1 clone showed that the apoptosis of in vitro activated Th1 cells can be inhibited by neutralizing IFN-␥ with mAb, and that anti-IFN-␥ mAb can block the upregulation of Fas ligand expression on activated Th1 cells (45) . Recently, IFN-␥ has been shown to be required for induction of longterm allograft survival by T cell costimulation blockade, but this effect of IFN-␥ was Fas independent (46) . IFN-␥ has been shown to make tumor cells susceptible to Fas-induced apoptosis (47, 48) . Therefore, the role of IFN-␥ in IL-12-mediated GVHD protection may be to make host-reactive donor T cells susceptible to Fas-mediated cell death. The role of IFN-␥ in the IL-12-induced increase in Fas expression on donor CD4 T cells (11) and in the ability of IL-12 to induce apoptotic death of host-reactive donor T cells during GVHD induction is currently under investigation.
Overall, the data presented in this study demonstrate that donor-derived IFN-␥ is required for the protective effect of IL-12 against GVHD, but that IFN-␥ is not required for the induction of lethal acute GVHD. In addition, our studies show that IL-12 can transiently inhibit GVH alloreactivity induced by an IFN-␥-independent pathway. Both IL-12 and IFN-␥ are important regulatory cytokines of immune responses and have antitumor effects of their own (12, 49-54). Unlike most available means of GVHD prophylaxis, which are associated with increased rates of allograft failure and leukemic relapse (55) (56) (57) (58) , our previous studies showed that IL-12 can preserve graftversus-leukemia effects without compromising marrow engraftment while inhibiting GVHD in mice (9, 10) . Thus, the use of IL-12 might have the potential to overcome GVHD and thereby facilitate the HLA-mismatched allogeneic BMT in leukemic patients.
